NAD+ Therapy: Biomarker Context and Provider-Guided Personalization

Last reviewed: May 29, 2026

Last updated: May 29, 2026

Written by: Jay Hastings, CEO of PlexusDx

Jay Hastings is the CEO of PlexusDx, a precision health company focused on genetic testing, blood biomarker insights, and personalized wellness recommendations. He has more than 20 years of experience across healthcare innovation, genomics, laboratory operations, healthcare investing, and strategic finance.

Medically reviewed by: Jayden Lee, PharmD, EMBA

Jayden Lee, PharmD, EMBA, is the PlexusDx Medical Science Liaison with a PharmD and MBA specializing in pharmacogenomics and clinical product development, with a proven ability to bridge the gap between genomic research and practical patient outcomes. Dr. Lee has more than 10 years of professional experience in clinical pharmacy, academia, and research.

NAD+ (nicotinamide adenine dinucleotide) is a coenzyme central to cellular energy production and stress-response pathways. Preclinical research suggests NAD+ decline correlates with aging, yet human clinical data on supplementation remains limited and inconsistent across age groups and health conditions.

NAD+ therapy discussions often lack personalized context. PlexusDx believes precision wellness requires understanding your individual metabolic predispositions before committing to treatment protocols. Biomarker awareness and genetic insights can support more informed conversations with your healthcare provider about whether NAD+ therapy aligns with your health goals.

How NAD+ Functions in Cellular Energy and Aging Pathways

NAD+ serves dual roles: it enables ATP synthesis in mitochondria and acts as a substrate for sirtuins and PARPs, enzymes linked to DNA repair and stress resistance. As we age, NAD+ levels decline, particularly in muscle, brain, and liver tissues.

Animal studies show NAD+ precursors (NMN, NR) restore energy production and improve insulin sensitivity. However, human randomized controlled trials remain sparse, with most showing modest effects on exercise capacity or glucose metabolism at 6-12 week intervals.

Clinical Evidence: What Research Actually Shows

Published human trials include small cohorts (30-70 participants). A 2021 study in *Science* reported NMN supplementation improved muscle insulin sensitivity in prediabetic women. A 2023 trial showed NR may reduce cardiovascular disease risk markers in older adults, though effect sizes were modest.

Study Type	Key Finding	Sample Size	Limitation
Animal (in vivo)	NAD+ restoration improves mitochondrial function and lifespan in mice	N/A	Results rarely translate directly to humans
Human RCT (NMN)	Improved insulin sensitivity in prediabetic women	60 participants	Short duration (10 weeks); limited to one population
Human RCT (NR)	Reduced systolic blood pressure and aortic stiffness	120 participants	Modest effect size; unclear clinical significance
Observational	Lower NAD+ correlates with frailty in aged cohorts	500+ participants	Correlation does not prove supplementation restores function

Biomarkers and Metabolic Context for NAD+ Consideration

NAD+ efficacy may depend on underlying metabolic state. Patients with mitochondrial dysfunction, metabolic syndrome, or impaired glucose tolerance represent populations where NAD+ restoration might theoretically benefit. However, baseline NAD+ measurement remains research-grade and unavailable in most clinical settings.

Genetic predispositions in energy metabolism pathways—such as mitochondrial biogenesis genes (PGC1A) and glucose-handling variants—may influence how individuals respond to NAD+ therapy. Biomarker-informed evaluation can help clarify whether NAD+ aligns with your specific metabolic profile.

Safety, Dosing, and Who Should Consider NAD+ Therapy

Common NAD+ precursors (NMN, NR, NA) are generally well-tolerated at doses of 250-1000 mg daily. Reported side effects include mild nausea and headache. Long-term safety data beyond 12 months remains limited. NAD+ may interact with certain medications affecting cardiovascular or blood glucose regulation.

NAD+ therapy is not recommended during pregnancy, in patients with uncontrolled cancer, or in those on immunosuppressive regimens without provider oversight. Older adults, individuals with metabolic syndrome, and those experiencing cognitive decline represent populations of current research interest, though evidence for routine use remains preliminary.

How PlexusDx Supports a More Personalized Approach

PlexusDx's Precision Peptide Genetic Test reveals predispositions in peptide and metabolic signaling pathways, including variants affecting glucose homeostasis and energy metabolism. While this test does not predict NAD+ response directly, insights into your metabolic gene variants may help provide context for broader longevity and wellness decisions alongside NAD+ therapy conversations.

Genetic variants like FTO rs9939609 (fat mass and obesity-associated) and MC4R rs17782313 (melanocortin-4 receptor) influence energy intake and expenditure. Understanding these predispositions can support a more personalized conversation with your provider about whether NAD+ therapy complements your metabolic profile or whether other interventions (e.g., compounded GLP-1 peptides for metabolic support) may align better with your genetic context.

PlexusDx recommends discussing NAD+ therapy candidacy with a qualified healthcare provider, using biomarker and genetic insights as supporting information rather than sole determinants. This evidence-informed approach helps ensure NAD+ recommendations fit your individual metabolic foundation and health goals.

How Your Genetics Relate to GLP-1 Pathways

Not everyone responds to GLP-1 medications the same way. Genetic variants — including GIPR rs1800437, GLP1R rs6923761, FTO rs9939609, and MC4R rs17782313 — relate to the biological pathways these medications act on. These are pathway-level associations only and do not predict how much weight you will lose or how you will respond to any specific medication. PlexusDx maps 14 pathways, 49 peptides, and 150+ genetic insights so you and your provider can see how your genes relate to these pathways. It does not recommend, prescribe, or determine which medication, dose, or peptide is right for you. The PlexusDx Precision Peptide Genetic Test ($99 add-on after your first month, or $298 standalone) gives you and your provider pathway-level genetic context to support a more personalized conversation. Genetics is a guide, not a guarantee.

Access Personalized GLP-1 Care Through PlexusDx

PlexusDx offers seven prescription GLP-1 protocols to all 50 states — no membership, no insurance required, async intake or live consult. The Semaglutide Injection is $189/mo month-to-month, or from $149/mo on the 6-month plan. Medications are dispensed from licensed 503A compounding pharmacies following strict quality and safety standards. Add a Precision Peptide Genetic Test for $99 to personalize your protocol from day one.

Frequently Asked Questions

Is NAD+ supplementation proven to extend human lifespan?

No. Animal models show promise, but human longevity trials do not exist. Current evidence supports potential improvements in insulin sensitivity and vascular function, not lifespan extension. Provider guidance is essential before starting NAD+ therapy.

What is the difference between NAD+ precursors (NMN, NR, NA)?

NMN (nicotinamide mononucleotide), NR (nicotinamide riboside), and NA (nicotinic acid) are different molecules that cells convert to NAD+. NMN and NR show similar bioavailability; NA has longer clinical history but causes flushing. Research suggests comparable efficacy.

How much does NAD+ supplementation cost?

NAD+ precursor supplements typically range $30-$80 monthly depending on dose and brand. PlexusDx focuses on precision peptide and metabolic assessment; for NAD+ protocols, consult your healthcare provider about reputable sources and integration with personalized wellness plans.

Can NAD+ therapy interact with diabetes or blood pressure medications?

NAD+ may influence glucose and cardiovascular regulation, potentially affecting medication efficacy. Anyone on antidiabetic or antihypertensive agents should discuss NAD+ supplementation with their provider before starting. Medical supervision ensures safe dose and monitoring protocols.

How does the Precision Peptide Genetic Test relate to your GLP-1 pathway?

No. The test reveals predispositions in glucose, energy, and peptide pathways—not NAD+ metabolism directly. Results may help provide context for broader metabolic decisions and should be interpreted with your qualified healthcare provider as part of a comprehensive wellness strategy.

Related Reading

• Mthfr Methylation Longevity Aging Pathway
• Sirt1 Pathway Genetics Nad Cellular Repair
• What Is Longevity Aging Pathway Genetic Testing
• Longevity And Lifespan Nad Sirt3 Rs28365927

Medical and Editorial Standards

Medical review process: This article was reviewed for medical accuracy, scientific clarity, evidence alignment, and appropriate discussion of genetics, medications, supplements, biomarkers, and health-related claims.

Sources and evidence: PlexusDx educational content is developed using peer-reviewed research, clinical literature, reputable medical references, and, where applicable, public health or regulatory guidance.

Commercial transparency: PlexusDx offers genetic testing, blood biomarker testing, personalized supplement recommendations, and related precision wellness services. Product mentions are intended to help readers understand available options and should not be interpreted as medical advice.

Important disclaimer: PlexusDx educational content is for informational purposes only and should not be used as a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making decisions about medications, supplements, genetic testing, lab testing, or health-related care.